SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to heightened volatility driven by fresh military escalations between the U.S. and Iran, which are disrupting energy infrastructure and supply chains in the Middle East. Community discussion is sharply divided, with traders debating whether ongoing ceasefire rumors are manipulative tactics to suppress oil prices or if the supply-demand imbalance from record-low reserves will inevitably force prices higher.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as investors weigh strong demand for the Wegovy pillhighlighted by recent EU approval and aggressive global rolloutsagainst a legal battle with Eli Lilly over obesity drug advertising. While the stock remains volatile due to pipeline setbacks and competitive pressures, community sentiment is shifting toward long-term bullishness, with many pointing to favorable valuations and the potential for a guidance beat in upcoming financial results.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending due to the company's aggressive repurchase of convertible debt, which investors interpret as a signal of internal confidence and impending financial catalysts. The community is focused on the upcoming CMS decision regarding the New Technology Add-On Payment for Yartemlea and the potential for a favorable European Medicines Agency opinion, both of which are viewed as critical drivers for future revenue growth and market de-risking.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing high community engagement driven by recent defense contract wins and anticipation regarding potential future contracts with the Department of Defense. Investors are primarily focused on the company's strong book-to-bill ratio and rugged edge AI technology, viewing recent price volatility as a healthy consolidation period rather than a breakdown in the long-term growth thesis.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is facing significant market pressure as investors weigh concerns over high debt levels and cooling consumer demand for appliances. Sentiment remains polarized, with some traders anticipating further downside or potential bankruptcy, while contrarian investors are actively debating if the stock has reached a generational bottom or if aggressive cost-cutting measures are sufficient to stabilize the firm's long-term outlook.

Ambarella, Inc. engages in the development of low-power system-on-a-chip (SoC), semiconductors, and software for edge artificial intelligence (AI) applications and intelligent automation. The firm's products include video security, advanced driver assistance (ADAS), electronic mirror, drive recorder, driver or cabin monitoring, autonomous driving, and other robotics applications. It operates through the following geographical segments: Taiwan, Asia Pacific, Europe, North America, and United States. The company was founded by Feng Ming Wang and Leslie D. Kohn on January 15, 2004 and is headquartered in Santa Clara, CA.

Ambarella Inc

Ambarella Inc. is trending as investors digest a potential acquisition by NXP Semiconductors, which would bolster NXP's automotive edge AI and computer vision capabilities. While the stock has seen significant volatility amid the buyout rumors, the community is actively debating whether the company's valuation remains attractive or if the speculative premium has already been priced in.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group Inc. is trending as shares dropped sharply following FDA briefing documents that criticized the clinical trial data for its melanoma drug RP1, citing inflated response rates and design flaws ahead of an upcoming advisory committee meeting. The community is sharply divided, with many debating the impact of the FDA's negative review on approval odds while others discuss the potential for a short squeeze or further downside volatility.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest unprecedented Phase 3 data for its lead KRAS inhibitor, daraxonrasib, which significantly extended survival in previously treated metastatic pancreatic cancer. The community is buzzing over the stock's massive market valuation jump and intense speculation regarding potential multibillion-dollar M&A interest from major pharmaceutical players following these practice-changing results.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA approval of Auvelity for the treatment of agitation associated with Alzheimers dementia, a major milestone that significantly expands the drug's addressable market. The community is actively discussing the stock's long-term growth potential and commercial ramp-up, while analysts remain bullish as they prepare to adjust price targets ahead of upcoming earnings.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh geopolitical risks and supply disruptions in the Middle East against the company's strong long-term expansion plans. The community is actively debating the disconnect between the stock's valuation and the rising global demand for LNG, while keeping a close eye on the upcoming earnings report and potential impacts from regional energy infrastructure conflicts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates

Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +14.52% and +2.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why

Pacific Biosciences of California (PACB) reached $1.39 at the closing of the latest trading day, reflecting a +2.21% change compared to its last close.

Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.36, indicating a -5.56% shift from the previous trading day.

Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know

Pacific Biosciences of California (PACB) concluded the recent trading session at $1.49, signifying a -4.49% move from its prior day's close.

Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care

RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.

NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers

Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.

Here's Why You Should Add Merit Medical Stock to Your Portfolio Now

MMSI's portfolio, acquisitions, R&D strategy and WRAPSODY upside support growth, though tariffs, China pressure and OEM headwinds persist.

WST Completes SmartDose Sale to AbbVie to Focus on Core Growth

West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.

Here's Why You Should Add PacBio Stock to Your Portfolio Now

PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.

CareDx Completes Naveris Acquisition and Expands Oncology Reach

CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.

$PACB Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.03 up 97.92% YoY
• Reported revenue of $37.18M up 0.07% YoY
• PacBio expects revenue for the full year 2026 to be in the range of $165M to $175M.

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Pacific Biosciences of California Inc

PacBio Stock Soars On Plans To Reduce Spending Over NIH Funding Uncertainty, Tariffs: Retail Is Overjoyed

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PACBPacific Biosciences of California Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest PACB News